InCVAX is under clinical development by Immunophotonics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect InCVAX’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 23 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 23 Nov 2022 increased InCVAX’s LoA and PTSR for Non-Small Cell Lung Cancer.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their InCVAX Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
inCVAX is under development for the treatment of solid tumors including melanoma, soft tissue sarcoma, hepatocellular carcinoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer and coronavirus disease 2019 (COVID-19) as vaccine adjuvant. It is a laser-guided cancer vaccine therapy that utilizes the combination of a laser treatment, followed by injection at the treated tumor site with an immunological stimulant (Protectin). The therapeutic candidate is administered by intratumor route. It was under development for the treatment of stage III and IV metastatic breast cancer.
Immunophotonics is a biotech company that designed to transform tumor ablation into hypnotherapy for cancer and develops immunotherapy-based treatments for cancer. Immunophotonics is headquartered in St. Louis, Missouri, the US.
Quick View InCVAX LOA Data
|Highest Development Stage|